Vorasidenib, a pan-IDH1/IDH2 inhibitor, displays CNS penetration and successfully demonstrated itself as a potential treatment for IDH-mutant glioma pending FDA approval [10]. This evidence concerns the gene IDH1 and central nervous system cancer.